The story of Theranos may be the biggest case of corporate fraud since Enron.
"A great and at times almost unbelievable story of scandalous fraud, surveillance, and legal intimidation at the highest levels of American corporate power. Bad Blood offers a sobering warning of where that type of thinking can lead." power brokers know next to nothing about science or technology but increasingly view Silicon Valley tech as a deus ex machina for some of the world’s most complicated challenges. While Bad Blood is worth reading for its own merits-it’s a stunning feat of journalism that reads like a thriller-it also says a lot about Washington’s facile relationship with Silicon Valley.
"The definitive account of Theranos’s downfall, detailing its motley crew of executives, legal knife fights, dramatic PR stunts, and skullduggery. Roger Lowenstein, The New York Times Book Review "Chilling. Carreyrou tells virtually to perfection… Reads like a West Coast version of All the President's Men." Bethany McLean, bestselling coauthor of The Smartest Guys in the Room and All the Devils Are Here No matter how bad you think the Theranos story was, you'll learn that the reality was actually far worse." "You will not want to put this riveting, masterfully reported book down. Bad Blood is wild, and more happens on one page than in many other entire books." -Margaret Lyons, The New York Times " Bad Blood is the real be-all end-all of Theranos information…. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings-from journalists to their own employees. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. There was just one problem: The technology didn’t work.
Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Carreyrou tells virtually to perfection.” - The New York Times Book Review With a new Afterword covering her trial and sentencing, bringing the story to a close. The gripping story of Elizabeth Holmes and T heranos -one of the biggest corporate frauds in history-a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist.
0 kommentar(er)
